Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 71,278 shares at $18.51 ($1.3M) on 2020-10-21, disclosed to the SEC on 2020-10-22.
Open-market sale of $1.3M KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.27 | 11,218 | $194K | 15.1% |
| 2 | $17.27 | 11,218 | $194K | 15.1% |
| 3 | $18.01 | 4,776 | $86K | 6.7% |
| 4 | $18.01 | 4,776 | $86K | 6.7% |
| 5 | $17.48 | 5,800 | $101K | 7.9% |
| 6 | $18.51 | 13,052 |
| $242K |
| 18.8% |
| 7 | $18.51 | 13,052 | $242K | 18.8% |
| 8 | $19.01 | 3,693 | $70K | 5.5% |
| 9 | $19.01 | 3,693 | $70K | 5.5% |
| Total | $18.02 avg | 71,278 | $1.3M | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |